79221183 - VACSAF

Information

• Trademark
• 79221183

• Source

• Serial Number

  79221183

• Registration Number

  5651894

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations

• Filing Date

  October 27, 2017
  7 years ago

• Registration Date

  January 15, 2019
  5 years ago

• Transaction Date

  January 15, 2024
  11 months ago

• Status Date

  January 15, 2019
  5 years ago

• Published for Opposition Date

  October 30, 2018
  6 years ago

• Location Date

  January 15, 2019
  5 years ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  MAYER, DAVID COREY

• Attorney Docket Number

  008814.00006

  Attorney Name

  Helen Hill Minsker

  Law Office Assigned Location Code

  N30

• Owners

  • SISAF LIMITED

Case File Statements

• GS0051: Antiviral pharmaceutical preparations, anti-infective pharmaceutical preparations, anti-inflammatory pharmaceutical preparations, antiseptic pharmaceutical preparations, antibacterial pharmaceutical preparations, antibiotic pharmaceutical preparations, antifungal pharmaceutical preparations, and anti-fibrotic pharmaceutical preparations; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment and prevention of cardiovascular diseases and disorders, musculoskeletal diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, pulmonary diseases and disorders, immune system related diseases and disorders, hematological diseases and disorders, oncological diseases and disorders, urological diseases and disorders, gastro-intestinal diseases, eye diseases and conditions, heart rhythm disorders, kidney diseases, nephropathic diseases, hematological disorders, diabetes, hypertension, skin disorders, damaged skin and tissue, wrinkles, wounds and allergies, insect bites, dermatological diseases and disorders, HIV, cancer and tumors, bone diseases, arthritis, cardiopulmonary diseases and disorders, infectious diseases, blood disorders, pain, sepsis, alopecia, obesity, cognitive disorders and diseases, neurological disorders, hormonal disorders, disorders of the autoimmune system, metabolic system diseases and disorders, endocrine system diseases and disorders, genitourinary system diseases and disorders; Preparations in the nature of animal feed supplements containing trace elements; Preparations in the nature of human vaccine preparations containing trace elements; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals, nutraceutical and veterinary products; Drug delivery agents consisting of nanoparticle compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; Drug delivery agents consisting of silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; Drug delivery agents consisting of porous silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of compounds for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; Chemical, biochemical, biological and pharmaceutical substances for medicinal use being pharmaceutical preparation stabilizers
• PM0001: VAC SAF; VACCINE SAFE
• GS0011: Chemicals and chemical preparations for use in industry, science and research; Biochemical substances and biochemical preparations for use in industry, science and research, namely, excipients for use in the manufacture of pharmaceutical preparations, cosmetic preparations, nutraceutical preparations, veterinary preparations, dietary supplements, foods and pharmaceutical preparations for topical use; Chemical preparations for pharmaceutical, medical and veterinary research in the nature of reagents and substrates, namely, chemical compounds for use in patterning at nano scale or near nano scale; Silicon for use in industry, science and research; Silicon nanoparticle materials, namely, silicon and silicon-based chemical compounds for use in industry, science and research; Porous silicon nanoparticle materials, namely, silicon and silicon-based chemical compounds for use in industry, science and research; Chemical materials, namely, chemical catalysts for carrying and delivery of chemical, biochemical and biological substances for use in industry and not for medical or veterinary use; Silicon for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Nanoparticle materials, namely, silicon-based chemical compounds for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Silicon nanoparticle materials being silicon-based chemical compounds for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Porous silicon nanoparticle materials being silicon-based chemical compounds for stabilising enzymes of chemical, biochemical and biological substances for use in industry and for scientific research purposes; Chemicals and chemical preparations, namely, reagents and catalysts for pharmaceutical research purposes; Chemicals and chemical preparations, namely, reagents and catalysts for scientific research in the field of medicine, veterinary and pharmaceutics; Excipient for use in the manufacture of pharmaceutical products, including for the manufacture of vaccines and veterinary preparations

Case File Event Statements

• 1/15/2024 - 11 months ago

  31 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3

• 5/17/2019 - 5 years ago

  30 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO

• 5/1/2019 - 5 years ago

  29 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 4/30/2019 - 5 years ago

  28 - FINAL DISPOSITION PROCESSED Type: FIMP

• 4/15/2019 - 5 years ago

  27 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 1/15/2019 - 5 years ago

  26 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 12/14/2018 - 6 years ago

  25 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 10/30/2018 - 6 years ago

  24 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 10/30/2018 - 6 years ago

  23 - PUBLISHED FOR OPPOSITION Type: PUBO

• 10/26/2018 - 6 years ago

  22 - NOTIFICATION PROCESSED BY IB Type: GPNX

• 10/10/2018 - 6 years ago

  21 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 10/10/2018 - 6 years ago

  20 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R

• 10/10/2018 - 6 years ago

  19 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 9/18/2018 - 6 years ago

  18 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 9/18/2018 - 6 years ago

  17 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 9/18/2018 - 6 years ago

  16 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 9/18/2018 - 6 years ago

  15 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 9/18/2018 - 6 years ago

  14 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 8/31/2018 - 6 years ago

  13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 8/31/2018 - 6 years ago

  12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 8/30/2018 - 6 years ago

  11 - ASSIGNED TO LIE Type: ALIE

• 8/15/2018 - 6 years ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 3/9/2018 - 6 years ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 2/16/2018 - 6 years ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 2/16/2018 - 6 years ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 2/13/2018 - 6 years ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 2/12/2018 - 6 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 2/6/2018 - 6 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 11/29/2017 - 7 years ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 11/25/2017 - 7 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 11/16/2017 - 7 years ago

  1 - SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB Type: SDRC